Contingent valuation of inhaled insulin: a Canadian perspective

References

• Center for Chronic Disease Prevention and Control, Population and Public Health Branch. Diabetes in Canada, 2nd edn. Health Canada, Ottawa, ON 2002
   Google Scholar
• Dawson KG, Gomes D, Gerstein H. The economic cost of diabetes in Canada, 1998. Diabetes Care 2002; 25: 1303–1307
   PubMed Web of Science ®Google Scholar
• Hirsch IB, Farkas-Hirsch R, Skyler JS. Intensive insulin therapy for treatment for type 1 diabetes. Diabetes Care 1990; 13: 1265–1283
   PubMed Web of Science ®Google Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine 1993; 329: 977–986
   PubMed Web of Science ®Google Scholar
• Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837–853 Erratum. Lancet 1999; 354: 602.]
   PubMed Web of Science ®Google Scholar
• Weingarten C, Moufti A, Desjeux JF, et al. Oral ingestion of insulin liposomes: effects of the administration route. Life Sciences 1981; 28: 2747–2752
   PubMed Web of Science ®Google Scholar
• Pozzilli P, Modi P, Manfrini S. Pharmacokinetic of oral spray insulin vs. regular and lispro insulin in type 1 diabetes. Diabetes 2002; 51: A48
   Google Scholar
• Modi P, Guevara-Aguiree J, Guevara M. Oral insulin spray as a meal insulin in treatment of type 2 diabetes. Diabetes 2002; 51: A108
   Google Scholar
• Moses AC, Gordon GS, Carey MC. Intranasal aerosolized insulin: mixed-meal studies and long term use in type 1 diabetes. Diabetes 1983; 32: 1040–1047
   PubMed Web of Science ®Google Scholar
• Coates PA, Ismail IS, Luzio SD, et al. Intranasal insulin: the effects of three dose regimens on postprandial glycaemic profiles in type II diabetic patients. Diabetic Medicine 1995; 12: 235–239
   PubMed Web of Science ®Google Scholar
• Dyer AM, Hinchcliffe P, Watts P, et al. Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharmaceutical Research 2002; 19: 998–1008
   PubMed Web of Science ®Google Scholar
• Mitragotri S, Blankschtein D, Langer R. Ultrasound-mediated transdermal protein delivery. Science 1995; 269: 850–853
   PubMed Web of Science ®Google Scholar
• Cevc G. Transdermal drug delivery of insulin with ultradeformable carriers. Clinical Pharmacokinetics 2003; 42: 461–474
   PubMed Web of Science ®Google Scholar
• Weiss SR, Berger S, Cheng SL. Adjunctive therapy with inhaled human insulin in type 2 diabetic patients failing oral agents; a multicenter phase II trial. Diabetes 1999; 48: A12
   Google Scholar
• Cefalu WT, Skyler JS, Kourides IA, et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Annals of Internal Medicine 2001; 134: 203–207
   PubMed Web of Science ®Google Scholar
• Cavallo MG, Coppolino G, Romeo S, et al. Inhaled insulin in type 1 diabetes. Lancet 2001; 357: 1980
   PubMedGoogle Scholar
• Laube BL. Treating diabetes with aerosolized insulin. Chest 2001; 120((3 Suppl.))99S–106S
   Web of Science ®Google Scholar
• Skyler JS, Weinstock RS, Raskin P, et al. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 2005; 28: 1630–1635
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Bergenstal RM, Cefalu WT, et al. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care 2005; 28: 1922–1928
   PubMed Web of Science ®Google Scholar
• Gerber RA, Cappelleri JC, Kourides IA, et al. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. Diabetes Care 2001; 24: 1556–1559
   PubMed Web of Science ®Google Scholar
• Simonson DC, Hayes JF, Turner RR, et al. Treatment satisfaction and preference in type 2 diabetes: a randomized trial or oral agents vs. inhaled insulin. Diabetes 2001; 50: A131
   PubMed Web of Science ®Google Scholar
• Testa MA, Turner RR, Hayes JF, et al. Patient satisfaction and quality of life in type 1 diabetes: a randomized trial of injectable versus inhaled insulin. Diabetes 2001; 50: A45
   Web of Science ®Google Scholar
• Sadri H, MacKeigan LD, Leiter LA, et al. Willingness to pay for inhaled insulin: a contingent valuation approach. PharmacoEconomics 2005; 23: 1215–1227
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies. Canadian Agency for Drugs and Technologies in Health, OttawaCanada 2006
   Google Scholar
• Johannesson M. The contingent-valuation method. Medical Decision Making 1993; 13: 311–312
   PubMed Web of Science ®Google Scholar
• Davey P, Grainger D, MacMillan J, et al. Economic evaluation of insulin lispro versus neutral (regular) insulin therapy using a willingness-to-pay approach. PharmacoEconomics 1998; 13: 347–358
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Longo CJ, Grossman LD. The economic value of a new insulin preparation, Humalog Mix 25: measured by a willingness-to-pay approach. PharmacoEconomics 2000; 18: 275–287
   PubMed Web of Science ®Google Scholar
• Ministry of Health and Long-Term Care. Ontario Drug Benefit Formulary/Comparative Drug Index. Publications Ontario;, OttawaCanada 2003
   Google Scholar
• Stålhammar N-O. An empirical note on willingness to pay and starting-point bias. Medical Decision Making 1996; 16: 242–247
   PubMed Web of Science ®Google Scholar
• Mitchell RC, Carson RT. Resources for the Future. A Contingent Valuation Estimate of National Freshwater Benefits. Technical Report to the US Environmental Protection Agency;. 1984
   Google Scholar
• Cappelleri JC, Cefalu WT, Rosenstock J, et al. Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clinical Therapeutics 2002; 24: 552–564
   PubMed Web of Science ®Google Scholar
• Riddle MC. The underuse of insulin therapy in North America. Diabetes/Metabolism Research and Reviews 2002; 18((Suppl. 3))S42–S49
   Google Scholar
• Zambanini A, Newson RB, Maisey M, et al. Injection related anxiety in insulin-treated diabetes. Diabetes Research and Clinical Practice 1999; 46: 239–246
   PubMed Web of Science ®Google Scholar
• Thernlund G, Dahlquist G, Hågglöf B, et al. Psychological reactions at the onset of insulin-dependent diabetes mellitus in children and later adjustment and metabolic control. Acta Paediatrica 1996; 85: 947–953
   PubMed Web of Science ®Google Scholar
• Zethraeus N. Willingness to pay for hormone replacement therapy. Health Economics 1998; 7: 31–38
   PubMed Web of Science ®Google Scholar
• Kartman B, Andersson F, Johannesson M. Willingness to pay for reductions in angina pectoris attacks. Medical Decision Making 1996; 16: 248–253
   PubMed Web of Science ®Google Scholar
• Sach TH, Smith RD, Whynes DK. A ‘league table’ of contingent valuation results for pharmaceutical interventions: a hard pill to swallow? PharmacoEconomics 2007; 25: 107–127
   PubMed Web of Science ®Google Scholar
• Prosser LA, Ray GT, O’Brien M, et al. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. Pediatrics 2004; 113: 283–290
   PubMed Web of Science ®Google Scholar
• Carson RT. Contingent valuation: a user's guide. Environmental Science & Technology 2000; 34: 1413–1418
   Web of Science ®Google Scholar